文献速递肿瘤 PET/CT

18F-FDG与68Ga-生长抑素类似物PET/CT在梅克尔细胞癌患者中的比较研究

18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study.
PubMed 文献 · EJNMMI Res · 2018-07-21

回顾性纳入15例组织学确诊的梅克尔细胞癌患者,均行18F-FDG与68Ga-生长抑素类似物PET/CT用于分期、再分期或疗效评估。患者水平分析中,18F-FDG与68Ga-生长抑素类似物的灵敏度分别为8/8(100%)与8/8(100%),特异度分别为6/7(85.7%)与5/7(71.4%),差异无统计学意义。病灶水平分析中,18F-FDG检出67/75个病灶(89%),68Ga-生长抑素类似物检出69/75个(92%),差异无统计学意义。

要点

  • 18F-FDG与68Ga-生长抑素类似物PET/CT在梅克尔细胞癌诊断性能上相当。
  • 4例原发灶不明的梅克尔细胞癌患者中,两种示踪剂均未能识别原发灶。
  • 作者认为结果不支持以68Ga-生长抑素受体显像替代18F-FDG PET/CT。

核心结论

  • 初步数据提示18F-FDG与68Ga-生长抑素类似物PET/CT在梅克尔细胞癌中提供良好且相当的诊断性能,为梅克尔细胞癌复杂生物学增添有趣见解。
  • 这些结果并不提示18F-FDG PET/CT应被68Ga-生长抑素受体显像替代,后者应按临床指征追加进行,以契合「个体化医学」视角。

研究设计与样本

  • 回顾性评估15例组织学确诊的梅克尔细胞癌患者(12例男性、3例女性;中位年龄73岁,范围41-81岁),其中4例原发灶不明。
  • 患者均因分期、再分期或疗效评估接受18F-FDG与68Ga-生长抑素类似物PET/CT两种检查。
  • 以组织学或临床/影像随访作为最终诊断参考标准,对两种检查结果进行患者水平和病灶水平的定性分析与比较。

主要发现

  • 根据最终诊断,8/15例患者至少有一个梅克尔细胞癌病灶,7/15例无疾病证据。
  • 患者水平分析中,18F-FDG正确分类为阳性8/8例(灵敏度100%)、阴性6/7例(特异度85.7%);68Ga-生长抑素类似物正确分类为阳性8/8例(灵敏度100%)、阴性5/7例(特异度71.4%),两者差异无统计学意义。
  • 病灶水平分析中,18F-FDG检出67/75个病灶(89%),68Ga-生长抑素类似物检出69/75个(92%),差异无统计学意义。
  • 4例原发灶不明的梅克尔细胞癌患者中,两种示踪剂均未能识别原发灶部位。

局限性

  • 原文为初步数据。
  • 原文为回顾性评估。
  • 原文样本量为15例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluoro-deoxy-glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of 68Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of 18F-FDG and 68Ga-somatostatin analog PET/CT in MCC patients. RESULTS: Fifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both 18F-FDG and 68Ga-somatostatin analog PET/CT for staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, 18F-FDG and 68Ga-somatostatin analogs correctly classified as positive 8/8 (100% sensitivity) patients and as negative 6/7 (85.7% specificity) and 5/7 (71.4% specificity) patients, respectively, with no significant difference. On a lesion-based analysis, 18F-FDG detected 67/75 lesions (89%) and 68Ga-somatostatin analogs 69/75 (92%), with no significant difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site. CONCLUSIONS: Our preliminary data suggest that 18F-FDG and 68Ga-somatostatin analog PET/CT provide good and equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these results do not suggest that 18F-FDG PET/CT should be replaced by 68Ga-somatostatin receptor imaging, which should be performed in addition, according to clinical indication, to the perspective of "personalized medicine."

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Taralli S, Sollini M, Milella M, et al. 18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. EJNMMI Res. 2018. PMID: 30032450. doi:10.1186/s13550-018-0423-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。